AstraZeneca reaches settlement with Sandoz over fulvestrant

Pharmaceutical giant AstraZeneca announced on Wednesday that it has entered into an agreement with Sandoz and its affiliates to resolve litigation relating to Faslodex (fulvestrant).

The FTSE 100 firm said the litigation related to Sandoz’s generic fulvestrant product, for which it is seeking FDA approval.

“The US Faslodex patents in question are due to expire in January 2021, with paediatric exclusivity continuing until July 2021,” AstraZeneca’s board said in a statement.

“On 12 July 2016, the United States District Court for the District of New Jersey entered a consent judgment filed by AstraZeneca and Sandoz, which includes an injunction preventing Sandoz from launching a generic fulvestrant product until 25 March 2019, or earlier in some circumstances.”